Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases

E-ISSN： 1875-533x|25|4|525-539

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.25, Iss.4, 2018-02, pp. : 525-539

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chelating Agents for Neurodegenerative Diseases

Current Medicinal Chemistry, Vol. 19, Iss. 17, 2012-06 ,pp. : 2760-2772

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3509-3519

Bentham Science Publishers

Access to resources Recommend Favorite

Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases

Current Pharmaceutical Design, Vol. 17, Iss. 3, 2011-01 ,pp. : 230-245

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 6, 2003-12 ,pp. : 349-356

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting CNS Transporters for Treatment of Neurodegenerative Diseases

Current Pharmaceutical Design, Vol. 20, Iss. 10, 2014-03 ,pp. : 1523-1533

Bentham Science Publishers

Access to resources Recommend Favorite